Sorafenib inhibits the shedding of major histocompatibility complex class i-related chain a on hepatocellular carcinoma cells by down-regulating a disintegrin and metalloproteinase 9

Hepatology

Volumn 51, Issue 4, 2010, Pages 1264-1273

  Kohga, Keisuke ^a   Takehara, Tetsuo ^a   Tatsumi, Tomohide ^a   Ishida, Hisashi ^a   Miyagi, Takuya ^a   Hosui, Atsushi ^a   Hayashi, Norio ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

A DISINTEGRIN AND METALLOPROTEINASE 9; ADAM PROTEIN; HLA A ANTIGEN; MAJOR HISTOCOMPATIBILITY COMPLEX CLASS I RELATED CHAIN A; SMALL INTERFERING RNA; SORAFENIB; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CELL DIVISION; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; DOWN REGULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INDEL MUTATION; LIVER CELL CARCINOMA; NATURAL KILLER CELL; PLASMID; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SITE DIRECTED MUTAGENESIS; SUPERNATANT; UPREGULATION; WESTERN BLOTTING;

ADAM PROTEINS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DIPEPTIDES; DOWN-REGULATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; HYDROXAMIC ACIDS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MEMBRANE PROTEINS; PROTEIN KINASE INHIBITORS; PYRIDINES;

EID: 77950613332     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23456     Document Type: Article

References (30)

1. Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in cirrhosis: incidence and trends. Gastroenterology 2004;127:S35-S50.
2. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-S16.
3. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T, et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 2006;131:461-469.
4. Doherty DG, O'Farrelly C. Innate and adaptive lymphoid cells in human liver. Immunol Rev 2000;174:5-20.
5. Mehal WZ, Azzaroli F, Crispe IN. Immunology of the healthy liver: old questions and new insights. Gastroenterology 2001;120:250-260.
6. Bauer S, Groh V, Wu J, Steinle A, Phillip JH, Lanier LL, et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999;285:727-729.
7. Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH, Spies T. Broad tumor-associated expression and recognition by tumor-derived y8T cells of MICA and MICB. Proc Natl Acad Sci USA 1999;96:6879-6884.
8. Jinushi M, Takehara T, Tatsumi T, Kanto T, Groh V, Spies T, et al. Expression of MICA and MICB in human hepatocellular carcinomas and their regulation by retinoic acids. Int J Cancer 2003;104:354-361.
9. Wu JD, Higgins LM, Steinle A, Cosman D, Haugk, K, Plymate SR Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest 2004;114:560-568.
10. Raffaghello L, Prigione I, Airoldi I, Camoriano M, Levreri I, Gambini C, et al. Downregulation and/or release of NKG2D ligands as an immune evasion strategy of human neuroblastoma. Neoplasia 2004;6:558-568.
11. Ogasawara K, Lanier LL. NKG2D in NK and T cell-mediated immunity. J Clin Immunol 2005;25:534-540.
12. Caudert JD, Held W. The role of the NKG2D receptor for tumor immunity. Semin Cancer Biol 2006;16:333-343.
13. Groh V, Wu J, Yee C, Spies T. Tumor-derived soluble MIC ligands impair expression of NKG2D and T cell activation. Nature 2002;419:734-738.
14. Salih HR, Rammensee HG, Steinle A. Downregulation of MICA on human tumors by proteolytic shedding. J Immunol 2002;169:4098-4102.
15. Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee HG, et al. Functional expression and release of ligands for activating immunore-ceptor NKG2D in leukemia. Blood 2003;102:1389-1396.
16. Jinushi M, Takehara T, Tatsumi T, Hiramatsu N, Sakamori R, Yamaguchi S, et al. Impairment of natural killer cell and dendritic cell functions by soluble form of MHC class I-related chain A in advanced human hepatocellular carcinoma. J Hepatol 2005;43:1013-1020.
17. Kohga K, Takehara T, Tatsumi T, Ohkawa K, Miyagi T, Hiramatsu N, et al. Serum levels of soluble major histocompatibility complex (MHC) class I-related chain A in patients with chronic liver disease and changes during transcatheter arterial embolization for hepatocellular carcinoma. Cancer Sci 2008;99:1643-1649.
18. Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant disease. Int J Cancer 2006;118:684-687.
19. Waldhauer I, Goehlsdorf D, Gieseke F, Weinschenk T, Wittenbrink M, Ludwig A, et al. Tumor-associated MICA is shed by ADAM proteases. Cancer Res 2008;68:6368-6376.
20. Kohga K, Takehara T, Tatsumi, T, Miyagi T, Ishida H, Ohkawa K, et al. Anti-cancer chemotherapy inhibits MICA ectodomain shedding by down-regulating ADAM10 expression in hepatocellular carcinoma. Cancer Res 2009;69:8050-8057.
21. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359: 378-390.
22. Suemizu H, Radosavljevic M, Kimura M, Sadahiro S, Yoshimura S, Bahram S, et al. A basolateral sorting motif in the MICA cytoplasmic tail. Proc Natl Acad Sci USA 2002;99:2971-2976.
23. Mochizuki S, Okada Y. ADAMs in cancer cell proliferation and progression. Cancer Sci 2007;98:161-167.
24. Lanier LL. NK cell receptors. Annu Rev Immunol 1998;16:359-393.
25. Ferlazzo G, Munz C. NK cell compartments and their activation by dedndritic cells. J Immunol 2004;172:1333-1339.
26. Devaux PF, Herrmann A, Ohlwein N, Kozlov MM. How lipid flippases can modulate membrane structure. Biochim Biophys Acta 2008;1778: 1591-1600.
27. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/ PRF/5. Cancer Res 2006;66:11851-11858.
28. Tanaka S, Arii S. Molecular targeted therapy for hepatocellular carcinoma. Cancer Sci 2009;100:1-8.
29. Tatsumi T, Takehara T, Yamaguchi S, Sasakawa A, Sakamori R, Ohkawa K, et al. Intrahepatic delivery of a-galactosylceramide-pulsed dendritic cells suppresses liver tumor. HEPATOLOGY 2007;45:22-30.
30. Miyagi T, Takehara T, Tatsumi T, Kanto T, Suzuki T, Jinushi M, et al. CD1d-mediated stimulation of natural killer T cells selectively activates hepatic natural killer cells to eliminate experimentally disseminated hepatoma cells in murine liver. Int J Cancer 2003;106:81-89.